Integrin β3 and its ligand regulate the expression of uPA through p38 MAPK in breast cancer

APMIS

Volumn 118, Issue 12, 2010, Pages 909-917

  Wang, Rui ^a   Li, Zhao Qing ^b   Han, Xu ^a   Li, Bai Lin ^a   Mi, Xiao Yi ^a   Sun, Li Mei ^a   Song, Min ^a   Han, Yan ChuN ^a   Zhao, Yan ^a   Wang, En Hua ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Breast cancer; Integrin; P38; TN

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; BETA3 INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE P38; TENASCIN; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; WESTERN BLOTTING;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL SURVIVAL; CHI-SQUARE DISTRIBUTION; ENZYME INHIBITORS; FEMALE; FORMAZANS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; INTEGRIN BETA3; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RETROSPECTIVE STUDIES; TENASCIN; TETRAZOLIUM SALTS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 78649501379     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2010.02687.x     Document Type: Article

References (43)

1. Edelman JM, Dimilla PA, AS M. The integrin cell adhesion molecules. In: Richardson PD, Steiner M, editors. Principles of Cell Adhesion [M]. Boca Raton, Ann Arbor, London: CRC Press, 1995: 163-86.
2. Lundin M, Nordling S, Lundin J, Haglund C. Tenascin-C expression and its prognostic significance in colorectal cancer. Oncology 2007;72:403-9.
3. Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer 2003;105:53-60.
4. Calvo A, Catena R, Noble MS, Carbott D, Gil-Bazo I, Gonzalez-Moreno O, et al. Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene 2008;27:5373-84.
5. Ishiwata T, Takahashi K, Shimanuki Y, Ohashi R, Cui R, Takahashi F, et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer. Anticancer Res 2005;25:489-95.
6. Koljonen V, Böhling T, Tukiainen E, Haglund C, Jahkola T. Tenascin-C expression in Merkel cell carcinoma lymph node metastasis. APMIS 2006;114:39-42.
7. Wang JY, Zhang ZY, Xu KS, Sun XH, Yang GY, Niu WB, et al. Suppression of integrin alphaupsilonbeta6 by RNA interference in colon cancer cells inhibits extracellular matrix degradation through the MAPK pathway. Int J Cancer 2008;123:1311-17.
8. Sun HW, Li CJ, Chen HQ, Lin HL, Lv HX, Zhang Y, et al. Involvement of integrins, MAPK, and NF-kappaB in regulation of the shear stress-induced MMP-9 expression in endothelial cells. Biochem Biophys Res Commun 2007;353:152-8.
9. Wang HQ, Bai L, Shen BR, Yan ZQ, Jiang ZL. Coculture with endothelial cells enhances vascular smooth muscle cell adhesion and spreading via activation of beta1-integrin and phosphatidylinositol 3-kinase/Akt. Eur J Cell Biol 2007;86:51-62.
10. Scherberich A, Tucker RP, Degen M, Brown-Luedi M, Andres AC, Chiquet-Ehrismann R. Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene 2005;24:1525-32.
11. Ruiz C, Huang WT, Hegi ME, Lange K, Hamou MF, Fluri E, et al. Differential gene expression analysis reveals activation of growth promoting signaling pathways by tenascin-C. Cancer Res 2004;64:7377-85.
12. v integrin, p38 mitogen-activated protein kinase, and urokinase Plasminogen activator are functionally linked in invasive breast cancer cells. J Biol Chem 2001;276:47901-5.
13. Turck N, Lefebvre O, Gross I, Gendry P, Kedinger M, Simon-Assmann P, et al. Effect of laminin-1 on intestinal cell differentiation involves inhibition of nuclear nucleolin. J Cell Physiol 2006;206:545-55.
14. Shin BA, Yoo HG, Kim HS, Kim MH, Hwang YS, Chay KO, et al. p38MAPK pathway is involved in the urokinase plasminogen activator expression in human gastric SNU-638 cells. Oncol Rep 2003;10:1467-71.
15. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, et al. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 2007;31:441-9.
16. Behren A, Binder K, Vucelic G, Herberhold S, Hirt B, Loewenheim H, et al. The p38 SAPK pathway is required for Ha-ras induced in vitro invasion of NIH3T3 cells. Exp Cell Res 2005;303:321-30.
17. Tavassoli FA, Devilee P. WHO Classification of Tumours. Pathology and Genetics, Tumours of the Breast and Female Genital Organs. Steinfurt: IARC Press, 2003.
18. Kumamoto H, Ooya K. Immunohistochemical detection of phosphorylated JNK, p38MAPK, and ERK5 in ameloblastic tumors. J Oral Pathol Med 2007;36:543-9.
19. He Y, Liu XD, Chen ZY, Zhu J, Xiong Y, Li K, et al. Interaction between cancer cells and stromal fibroblasts is required for activation of the uPAR-uPA-MMP-2 cascade in pancreatic cancer metastasis. Clin Cancer Res 2007;13:3115-24.
20. Savaris RF, Pedrini JL, Flores R, Fabris G, Zetter CG. Expression of alpha 1 and beta 3 integrins subunits in endometrium of patients with tubal phimosis or hydrosalpinx. Fertil Steril 2006;85:188-92.
21. Ohno Y, Izumi M, Yoshioka K, Ohori M, Yonou H, Tachibana M. Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma. Oncol Rep 2008;20:511-16.
22. Gui GP, Puddefoot JR, Vinson GP, Wells CA, Carpenter MR. In vitro regulation of human breast cancer cell adhesion and invasion via integrin receptors to the extracellular matrix. Br J Surg 1995;82:1192-6.
23. Horibe M, Sawa T, Kataoka M, Kido J, Nagata T. Regulation of tenascin expression in cultured rat dental pulp cells. Odontology 2004;92:22-6.
24. Nishio T, Kawaguchi S, Yamamoto M, Iseda T, Kawasaki T, Hase T. Tenascin-c regulates proliferation and migration of cultured astrocytes in a scratch wound assay. Neuroscience 2005;132:87-102.
25. 1 integrin and PI3-kinase. Invest Ophthalmol Vis Sci 2003;44:1704-15.
26. Ishii T, Uto T, Mori K, Fujikawa R. Integrin-linked kinase is involved in lactoferrin-induced anchorage-independent cell growth and survival in PC12 cells. Life Sci 2009;84:530-6.
27. Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V, Brünner N. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 1996;14:297-307.
28. Bergamo A, Masi A, Dyson PJ, Sava G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int Oncol 2008;33:1281-9.
29. Hood JD, Cheresh DA. Role of integrins in cell invasion and migration. Nat Rev Cancer 2002;2:91-100.
30. Haritopoulos KN, Lazaris AC, Kavantzas N, Tseleni-Balafouta S, Thomopoulou G, Aroni K. ICAM-1 and beta(3) integrin immunoexpression in malignant melanoma cells: can they be used as additional predictors? APMIS 2003;111:421-9.
31. Sato T, Miwa A. Ets-1 and integrin beta3 for lung metastasis from colorectal cancer. APMIS 2002;110:347-53.
32. Chiquet-Ehrismann R, Makie EJ, Pearson CA, Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986;47:131-9.
33. Galoian KA, Garamszegi N, Garamszegi SP, Scully SP. Molecular mechanism of tenascin-c action on matrix metalloproteinase-1 invasive potential. Exp Biol Med (Maywood) 2007;232:515-22.
34. Ria R, Vacca A, Ribatti D, Di Raimondo F, Merchionne F, Dammacco F. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. Haematologica 2002;87:836-45.
35. Cosgrove D, Meehan T, Delimont D, Pozzi A, Chen X, Rodgers KD, et al. Integrin alpha1beta1 regulates matrix metalloproteinases via P38 mitogen-activated protein kinase in mesangial cells: implications for Alport syndrome. Am J Pathol 2008;172:761-73.
36. Mainiero F, Colombara M, Antonini V, Strippoli R, Merola M, Poffe O, et al. p38 MAPK is a critical regulator of the constitutive and the beta4 integrin-regulated expression of IL-6 in human normal thymic epithelial cells. Eur J Immunol 2003;33:3038-48.
37. Lightner VA, Marks JR, McCachren SS. Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. Exp Cell Res 1994;210:177-84.
38. Adams M, Jones JL, Wslker RA, Pringle JH, Bell SC. Changes in tenascin-c isoform expression in invasive and preinvasive breast disease. Cancer Res 2002;62:3289-97.
39. Bodet C, Andrian E, Tanabe S, Grenier D. Actinobacillus actinomycetemcomitans lipopolysaccharide regulates matrix metalloproteinase, tissue inhibitors of matrix metalloproteinase, and plasminogen activator production by human gingival fibroblasts: a potential role in connective tissue destruction. J Cell Physiol 2007;212:189-94.
40. Suarez-Cuervo C, Merrell MA, Watson L, Harris KW, Rosenthal EL, AVäänänen HK, et al. Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis 2004;21:525-33.
41. Dang D, Yang Y, Li X, Atakilit A, Regezi J, Eisele D, et al. Matrix metalloproteinases and TGFbeta1 modulate oral tumor cell matrix. Biochem Biophys Res Commun 2004;316:937-42.
42. Chiquet M, Sarasa-Renedo A, Tunc-Civelek V. Induction of tenascin-C by cyclic tensile strain versus growth factors: distinct contributions by Rho/ROCK and MAPK signaling pathways. Biochim Biophys Acta 2004;1693:193-204.
43. Yang Y, Dang D, Mogi S, Ramos DM. Tenascin-C deposition requires beta3 integrin and Src. Biochem Biophys Res Commun 2004;322:935-42.